/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a blank check company incorporated on November 23, 2020, as a Cayman Islands exempted company, for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Our efforts to identify a prospective initial business combination target will not be limited to a particular industry, sector or…
$11.15
+$0.00 (+0.00%)
Price from 3 days ago
At 46x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
46.4x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
$8M
▲ +37.1% YoY
Op. Margin
—
ROIC
-1772.53%
▲ +5.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$387K
▲ +36.3% YoY
Net Debt
-$11K
Net Cash Position
Cash & Equiv.
$11K
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 17 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 46.4, GP-Act III Acquisition (GPAT)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
That depends on valuation and quality together, not either alone. you should weigh GPAT's valuation. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.